Stocks
Provectus Biopharmaceuticals, Inc.PVCT
OQBHealthcareBiotechnology$0.05
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oncology therapies, including a lead drug candidate for advanced melanoma and other solid tumors. Its proprietary platform also targets orphan diseases, and investors track it for clinical trial catalysts and regulatory milestones.
52W Range: $0.04-$0.08
Congressional Interest in Provectus Biopharmaceuticals, Inc. (PVCT)
No congressional trades have been disclosed for Provectus Biopharmaceuticals, Inc. (PVCT) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading PVCT?
No congressional trades found for this stock.